Biopheresis Technologies, Inc. Awarded Grant 'Biochance Plus-3' For The Development Of Its New Cancer Treatment Approach
HEIDELBERG, Germany--(BUSINESS WIRE)--BioPheresis GmbH has received a 2-year grant from the federal government for about 0.5 million Euros, to accelerate and expand the current and further work on a new cancer treatment with the company’s OncoSorb® column.